ARCA biopharma Announces Submission of Patent Application to U.S. Patent and Trademark Office Covering Treatment of Atrial Fibrillation in Patients With Heart Failure
May 13, 2019 09:00 ET
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., May 13, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
New U.S. Patent Issuance Granted to AXIM® Biotechnologies for Oral Care Composition Containing Cannabinoids
January 29, 2019 09:00 ET
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, Jan. 29, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (“AXIM® Biotech” or “AXIM”) (OTCQB: AXIM), a world leader in cannabinoid research and development, today announced that the...
Corbus Pharmaceuticals Announces Issuance of Composition of Matter Patent Related to Lenabasum
December 18, 2018 08:46 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Company’s vision is to become the leader in the treatment of inflammatory and fibrotic diseases by targeting the endocannabinoid systemLenabasum in late-stage clinical studies in three orphan...
Interpace Announces Notice of Allowance from U.S. Patent and Trademark Office Covering BarreGEN®
December 17, 2018 06:50 ET
|
Interpace Diagnostics Group, Inc.
BarreGEN® is Interpace’s Lead Molecular Diagnostic Pipeline Product for Barrett’s Esophagus Parsippany, NJ, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (“Interpace”)...
Tauriga Sciences Inc. to Register Trademark with USPTO to Support Launch of its Cannabis Infused Chewing Gum Product Line
December 07, 2018 11:29 ET
|
Tauriga Sciences
New York, NY, Dec. 07, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Tauriga Sciences, Inc. (TAUG) (“Tauriga” or the “Company”), engaged in building its business through the development,...
Hoverink Biotechnologies, Inc., today announced that they have completed an application with the USPTO for MAXKAFLEN®. Hoverink Biotechnologies, Inc plans to develop and commercialize MAXKAFLEN® a cattle and swine antibiotic.
November 12, 2018 14:30 ET
|
Hoverink Biotechnologies, Inc
Overview LOS ANGELES, CA, Nov. 12, 2018 (GLOBE NEWSWIRE) -- On September 26, 2018 We filed trademark applications covering: MAXKAFLEN® Word Mark MAXKAFLEN Goods and Services IC 005....
Hoverink Biotechnologies, Inc., today announced that they have completed an application with the USPTO for KAIYADRU®. Hoverink Biotechnologies, Inc plans to develop and commercialize KAIYADRU®
November 09, 2018 18:42 ET
|
Hoverink Biotechnologies, Inc
Overview On September 26, 2018 We filed trademark applications covering: LOS ANGELES, CA, Nov. 09, 2018 (GLOBE NEWSWIRE) -- KAIYADRU® Pharmaceutical preparations, namely,...
New U.S. Patent Allowance Granted to AXIM® Biotechnologies for Suppository Formulations Comprised of Cannabinoids
October 23, 2018 09:10 ET
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, Oct. 23, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (“AXIM® Biotech” or “AXIM”) (OTCQB: AXIM), a world leader in cannabinoid research and development, today announced that the...
Corbus Pharmaceuticals Announces Patent Issuance Covering Use of Lenabasum for the Treatment of Fibrotic Diseases Providing Exclusivity to 2034
October 03, 2018 09:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Company’s vision is to become the leader in the treatment of inflammatory and fibrotic diseases by targeting the endocannabinoid systemIntellectual property around pipeline targeting endocannabinoid...
Vivos Inc Obtains Trademark Protection for IsoPet®
July 30, 2018 06:00 ET
|
Vivos Inc.
Richland, WA, July 30, 2018 (GLOBE NEWSWIRE) -- Vivos Inc (OTC: RDGL) obtains IsoPet trademark protection. The U.S. Patent and Trademark Office (“USPTO”) issued the Certificate of Registration...